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We report a case of central retinal artery occlusion (CRAO) in a patient with a previous
history of severe COVID-19 disease. This disease has been associated with inflammatory-
induced homeostasis changes leading to endothelial dysfunction and a procoagulant state
with multi-organ involvement, but the burden of thromboembolic complications in COVID-
19 patients is currently unknown. The pathogenesis of retinal artery occlusions is a
multifactorial process where inflammation and hypercoagulation state are established
risk factors. Even if our experience may represent a coincidental relationship, it is likely that
COVID-19 patients could be at risk of developing retinal vascular occlusions. A focused
ophthalmological surveillance is advisable to prevent and manage this possible cause of
severe vision loss that has an important impact in health care system.
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INTRODUCTION
The ongoing pandemic of COVID-19 disease, caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has been associated with inflammatory-induced homeostasis changes
leading to a severe coagulopathy with multi-organ involvement (Levi et al., 2020). The pathogenesis
of retinal artery occlusions (RAO) is a multifactorial process where inflammatory and
hypercoagulation state are established risk factors (Flaxel et al., 2020). However, the effects of
COVID-19 inflammatory and pro-coagulant state over the retinal vascular system have not been
investigated yet. We report a case of a patient developing a central retinal artery occlusion after a
severe SARS-CoV-2 infection.
CASES PRESENTATION
The patient was a 59-year-old male, African ethnicity, with a previous longstanding history of
hypertension and hyperuricemia under treatment (Table 1). He was hospitalized four days after the
onset of fever, dry cough and progressive dyspnea. On admission, nasopharyngeal samples tested
positive for SARS-CoV-2 infection at polymerase chain reaction (PCR) molecular test and a
diagnosis of COVID-19 disease was made. Blood test revealed elevated inflammatory markers
and a procoagulant state (Table 2). The following day the conditions of the patient deteriorated and
he was transferred to the intensive care unit (ICU). Here he was intubated to receive mechanical
ventilation and he started a 5 days COVID-19 therapy with hydroxychloroquine 400 mg twice per
day, lopinavir/ritonavir association (200 and 50 mg respectively) twice per day, and a single
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intravenous dose of tocilizumab 800 mg. The ICU stay was
complicated by a bacterial pneumonia treated with broad-
spectrum antibiotics and a stage 3 acute renal injury that
required hemodialysis. The patient remained intubated for a
total of 10 days, five of which with prone positioning, and he
was later transferred to a neurorehabilitation department for
physical deconditioning and mental confusion after the
exclusion of cerebral ischemic events with computed
tomography angiography (CTA) of the cerebral arteries and
magnetic resonance imaging (MRI) of the brain.
One week after discharge from the hospital, he presented to
our emergency service complaining of painless vision loss in
the left eye. The patient noticed a decrease in visual function
during his neurorehabilitation stay, but he did not realize how
severe it was until he covered the right eye the day before. On
examination, the best-corrected visual acuity (BCVA, Snellen
equivalent) was 20/20 in the right eye and light perception in
the left eye. Right eye ophthalmologic examination was
unremarkable, while the left eye showed a nonreactive
mydriasis, and dilated fundus ophthalmoscopy revealed the
presence of severe arterial narrowing, retinal whitening in the
macular region with loss of the physiological macular reflex
and peripheral areas of retinal pigment epithelium
hyperpigmentation (Figure 1A). Optical coherence
tomography (OCT) showed temporal macular thinning in
both eyes and severe atrophy of the inner retina layers with
loss of the foveal depression in the left eye (Figures 1B,C). A
diagnosis of CRAO was hence made. Fluorescein angiography
(FA) performed 5 days later confirmed the diagnosis of CRAO
revealing severe delay in the filling of the retinal arteries and a
delayed arteriovenous transit time. In addition, findings
consistent with sickle cell retinopathy were remarked,
including areas of peripheral capillary nonperfusion,
arteriovenous anastomoses, and neovascular “sea-fans”
(Figure 2). Blood tests with hemoglobin electrophoresis
confirmed the presence of heterozygous hemoglobin S
(sickle cell trait), while the inflammatory markers
(erythrocyte sedimentation rate and C-reactive protein) were
within normal limits and not suggestive of an arteritic CRAO.
The patient was further evaluated by the stroke unit with brain
CTA and MRI of the encephalic trunk that did not reveal any
acute sign of vascular events. At one-month follow-up visit,
vision in the left eye improved to counting fingers and the left
pupil was still nonreactive. OCT scans confirmed the loss of the
foveal depression and showed ganglion cell layer atrophy
(Figure 3).
DISCUSSION
The COVID-19 disease has been described to induce inflammatory-
induced homeostasis changes that predispose to thrombotic disease
in both venous and arterial circulation (Levi et al., 2020; Levolger
et al., 2020). Post-mortem analysis showed evidence of direct viral
infection of the endothelial cells and diffuse endothelial
inflammation leading to endothelial dysfunction and a
procoagulant state (Varga et al., 2020). The risk of
thromboembolic events in COVID-19 patients is currently under
investigation, with preliminary results showing significantly
prolonged prothrombin time, high D-dimer levels and increased
concentrations of proinflammatory cytokines and biomarkers of
inflammation in patients with more severe disease, indicating the
likelihood of disseminated intravascular coagulation or thrombotic
microangiopathy (Connors and Levy, 2020; Levi et al., 2020). Even
thoughmost cases are affected by venous thromboembolism (Llitjos
et al., 2020), there are increasing reports of COVID-19 induced
arterial thromboembolic complications, highlighting the
thrombogenicity of SARS-CoV-2 infection (Levolger et al., 2020).
Lodigiani et al. (2020) in a cohort of 388 consecutive patients with
laboratory-proven COVID-19 requiring hospital admission,
disclosed a remarkable rate of venous and arterial
thromboembolic complications of approximately 8% despite the
use of anticoagulant prophylaxis (Lodigiani et al., 2020).
It is also well established that a considerable percentage of
subjects infected by the coronavirus develop a mild infection or are
asymptomatic, and in these cases the clinical and histopathology
data available are limited. Hence, the burden of thromboembolic
complications in COVID-19 patients is currently unknown, with
some authors suggesting that it may represent an underestimated,
large-scale issue (Lodigiani et al., 2020).
We report a case of a patient that developed a central retinal
artery occlusion after a severe COVID-19 disease. CRAO are
obstructions of retinal blood flow that result in severe vision loss.
They are divided in arteritic CRAO, mainly due to giant cells
arteritis, and non-arteritic CRAO, where platelet fibrin thrombi
or emboli as a result of atherosclerotic disease are responsible for
over two-third of all CRAO cases (Varma et al., 2013). However,
TABLE 1 | Patient’s clinical data on admission.
Age 59 Heart Rate 120 bpm
Sex Male Peripheral 02 Saturation 77%
Height 174 cm Blood Pressure 165/85 mmHg
Weight 99.4 kg Temperature 39.1°C
Previous Medical History Hypertension, Hyperuricemia
Domiciliary Therapy Amlodipine 10mg, Perindopril
10 mg, Torasemide 5mg,
Allopurinol 100 mg
TABLE 2 | Coagulation and inflammatory markers on admission.
Marker Level References Range
Thrombin time 18 s 14–19 s
aPTT 43 s 26–37 s
Platelet count 109 g/L 150–350 g/L
D-Dimer 2.059 ng/ml <500 ng/ml
Fibrinogen 5.9 g/L 2.0–4.0 g/L
White blood cell count 8.6 × 103/µl 4–10 × 103/µl
C-reactive protein 184 mg/L <10 mg/L
IL-1 alpha <1 pg/ml <6 pg/ml
IL-1RA 14,725 pg/ml <720 pg/ml
IL-6 42 pg/dl <11 pg/dl
IL-7 7 pg/dl <3 pg/dl
TNF-alpha <12 pg/ml <12 pg/ml
aPTT, activated partial thromboplastin time; IL, Interleukin; IL-1 RA; Interleukin-1
Receptor Antagonist; TNF, tumor necrosis factor.
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inflammatory and pro-coagulant state could also lead to the
development of retinal vascular occlusions (Flaxel et al., 2020).
Therefore, we might hypothesize that in the case we reported the
induction of a prothrombotic vascular endothelial
microenvironment by the COVID-19 disease could have
represented a precipitating factor causing the development of a
CRAO, similar to what observed in other organs such as
myocardial and renal microvasculature of COVID-19 patients
(Gheblawi et al., 2020).
Retinal vascular damage could be correlated to the ocular
expression of the angiotensin-converting enzyme 2 (ACE2).
SARS-CoV-2 is internalized by human cells after binding with
the ACE2, which acts as a functional receptor for the virus. The
expression of ACE2 has been detected in human aqueous humor
and in retinal tissue, particularly in pigmented epithelial cells,
photoreceptors and Müller cells. ACE2 plays an important role in
the vasoprotective axis of the renin–angiotensin system (RAS) as
it counterbalances the vasoconstrictive, proliferative, fibrotic and
proinflammatory effects of the ACE–Ang II–angiotensin II type 1
receptor (AT1R) axis generating Angiotensin 1–7 (Ang 1–7).
COVID-19 patients show a depletion of ACE2 function
directly following the binding with SARS-CoV-2 and indirectly
via shedding and proteolytic processing (Gheblawi et al., 2020).
This loss of ACE2 has several known deleterious effects. In fact,
there is an increase of Ang II and a decrease of Ang 1–7 levels in
tissues leading to exacerbation of hypertension. Moreover,
genetic ACE2 deficit correlates to an upregulation of
proinflammatory stimuli and atherogenesis mediators in
animal models, suggesting a key role of ACE2 in blocking
vascular inflammation and atherosclerosis (Gheblawi et al.,
2020). Furthermore, in animal models of diabetic retinopathy,
ACE2 overexpression inhibits the up-regulation of
proinflammatory factors and adhesion molecules in the retinal
circulation, while ACE2 deficiency is associated with profibrotic
and proinflammatory microvascular dysfunction and retinal
nerve fiber layer infarcts (Dominguez 2nd et al., 2016; Duan
et al., 2018).
To our knowledge, there are only two reports (Acharya et al.,
2020; Dumitrascu et al., 2020) of patients who developed a retinal
arterial occlusion in association with COVID-19 disease. In the
first report, the CRAO developed during the second week of
patient’s hospitalization, 3 days after the discharging from the
ICU, where the patient received COVID-19-directed therapy
including hydroxychloroquine, azithromycin, and tocilizumab.
In the second case, the onset of the CRAOwas in the sixth week of
hospitalization and the patient was under anticoagulant therapy
FIGURE 1 | Fundus photography of the left eye showing the presence of a pale optic disc, diffuse arterial narrowing, a mild ‘cherry-red spot’macula and peripheral
areas of retinal pigmented epithelium hyperpigmentation (A). IR and SD-OCT acquisition over the macular region of the same eye denoting atrophy of the inner retina
layers with loss of foveal depression and temporal macular thinning (B,C) [IR, infrared reflectance, SD-OCT, spectral domain optical coherence tomography].
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with apixaban after being treated with hydroxychloroquine,
tocilizumab and enoxaparin. In both cases, the authors did not
record the clinical findings with any imaging modality but
reported only the fundus examinations findings. In our case,
the exact timing of the CRAO could not be established, but we can
assume that it developed during the hospitalization when the
patient first reported the visual symptomology (Figure 4). In all
three cases the patients had received treatment with
hydroxychloroquine and tocilizumab prior to the CRAO onset.
We performed a research on the PubMed database and we did not
find any association between these two drugs and the induction of
thrombosis. Chronic use of hydroxychloroquine could induce
FIGURE 2 | Fluorescein angiography of the left eye 5 days after the diagnosis of CRAO showing a delayed arrival of the dye in the eye 43 s after the injection (A), peripheral
areas of capillary nonperfusion, arteriovenous anastomoses, and neovascular ‘sea-fans’ 4 min and 22 s after the dye injection (B) [CRAO, central retinal artery occlusion].
FIGURE 3 | Ganglion cell layer thickness analysis performed with the SD-OCT one month after the arterial occlusion. Within normal limits in the right eye (A) and
atrophic in the left eye (B) [SD-OCT, spectral domain optical coherence tomography].
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retinal toxicity, but its short-term usage on COVID-19 patients is
unlikely to induce retinal damage (Marmor, 2020). Moreover,
hydroxychloroquine has shown anti-thrombotic effects on
patients affected by antiphospholipid syndrome (Kravvariti
et al., 2020).
Even though it is not possible to assert with absolute certainty
the association between the CRAO and COVID-19 disease, we
have to highlight that the correlation is reasonable. Incidentally, the
patient was diagnosed with sickle cell disease, and this condition
could elicit retinal vascular occlusions, however these occlusions
occur predominantly in small caliber peripheral arterioles and its
association with CRAO is rare (Fine et al., 2000). We might
speculate that the inflammatory and procoagulant state
secondary to the COVID-19 could be the trigger for the retinal
artery occlusion in patients with cardiovascular risk factors.
In conclusion, because the association between thrombosis and
COVID-19 is becoming clearer, there are unresolved questions
regarding its possible impact on retinal pathophysiology, especially
in a population with multiple risk factors that might develop an
asymptomatic SARS-CoV-2 infection, and for which the routine
ophthalmic monitoring has been suspended (Recommendations
for Urgent and Nonurgent Patient Care, 2020). However, the
effects of COVID-19 inflammatory and pro-coagulant state over
the retinal vascular system are currently unknown. A focused post-
pandemic ophthalmological surveillance is advisable to prevent
and eventually manage this possible cause of retinal damage and
severe vision loss avoiding a negative impact in health care system.
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FIGURE 4 | Case report timeline.
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